Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

“Cetuximab, an anti-EGFR monoclonal antibody, demonstrated a significant advancement in managing mCRC when combined with various chemotherapy regimens. When used in conjunction with ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...

Erlotinib, an EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), improves survival in previously treated, advanced non-small-cell lung cancer (NSCLC) patients compared with placebo. Cetuximab ...

The results showed objective responses in 32 of 94 patients treated with the KRAS inhibitor adagrasib (Krazati) and the EGFR inhibitor cetuximab (Erbitux). An additional 48 patients had stable ...

and in combination with cetuximab (anti-EGFR) CAPTN-3 tri-specific platform yieldspromising preclinical data, supporting its differentiated benefit and well positioning it in the multi-specific ...

Purple Biotech Ltd. NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE ...